Black, Hispanic and white individuals treated with idecabtagene vicleucel for relapsed or refractory multiple myeloma experienced similar PFS and OS, according to study results published in Blood Advances.
The findings should be confirmed in larger samples of diverse patients with relapsed or refractory multiple myeloma with longer follow-up time, researchers concluded.
The clinical outcomes of standard-of-care treatment with the chimeric antigen receptor T-cell therapy among racially and ethnically diverse populations have been understudied, according to Lauren C. Peres, PhD, epidemiologist at
